Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 6/20 | 0.37 |
| ▸ | CDK8 | P49336 | 6/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17814178 | 0.83 | ACVRL1 (0.36) | CCNCCDK8MKNK1MKNK2CYP11B1 | |
| SCHEMBL17814175 | 0.78 | CYP11B1 (0.38) | CCNCCDK8CYP11B1CYP11B2CREBBP | |
| SCHEMBL17814162 | 0.77 | BRD4 (0.32) | MKNK1MKNK2CYP11B1CYP11B2 | |
| SCHEMBL17814205 | 0.77 | CYP11B1 (0.44) | CHEK1CYP11B1CYP11B2ADRA2AFGFR3 | |
| SCHEMBL17814084 | 0.76 | CDK8 (0.44) | CCNCCDK8CYP11B1CYP11B2CREBBP | |
| SCHEMBL17814124 | 0.76 | CCNC (0.45) | CCNCCDK8CYP11B1CYP11B2 | |
| SCHEMBL17802119 | 0.74 | CYP11B1 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL17814166 | 0.73 | CYP11B1 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL17814182 | 0.73 | CYP11B1 (0.35) | CCNCCDK8CYP11B1CYP11B2 | |
| SCHEMBL17814189 | 0.73 | CYP11B1 (0.37) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| EP-3227300-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-9890171-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-13 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| WO-2016089800-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267688-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, CYP11B2 | CCNC 2192/4885CDK8 2437/4885MKNK1 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.